These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 27029036)

  • 41. Decreased CD177
    Alayed K; Meyerson HJ
    Leuk Res; 2022 Jan; 112():106752. PubMed ID: 34896936
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
    Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
    Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
    Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Genomic aberrations in myelodysplastic syndromes and related disorders].
    Makishima H
    Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
    Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
    Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    Montalban-Bravo G; Kanagal-Shamanna R; Sasaki K; Patel K; Ganan-Gomez I; Jabbour E; Kadia T; Ravandi F; DiNardo C; Borthakur G; Takahashi K; Konopleva M; Komrokji RS; DeZern A; Kuzmanovic T; Maciejewski J; Pierce S; Colla S; Sekeres MA; Kantarjian H; Bueso-Ramos C; Garcia-Manero G
    Blood Adv; 2019 Mar; 3(6):922-933. PubMed ID: 30902805
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Correlation between U2AF1 Gene Mutation Characteristics and Clinical Manifestations and Prognosis in Patients with Myelodysplastic Syndrome].
    Zhao WS; Zhang YT; Jiang QL; Liu QF; Dai M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1977-1984. PubMed ID: 33283729
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
    Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
    Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Splicing Factor Mutations in Cancer.
    Bejar R
    Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
    [TBL] [Abstract][Full Text] [Related]  

  • 51. De novo childhood myelodysplastic/myeloproliferative disease with unique molecular characteristics.
    Ismael O; Shimada A; Hama A; Elshazley M; Muramatsu H; Goto A; Sakaguchi H; Tanaka M; Takahashi Y; Yinyan X; Fukuda M; Miyajima Y; Yamashita Y; Horibe K; Hanada R; Ito M; Kojima S
    Br J Haematol; 2012 Jul; 158(1):129-37. PubMed ID: 22571758
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes.
    Kuykendall AT; Tokumori FC; Komrokji RS
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):337-352. PubMed ID: 33641873
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular features of early onset adult myelodysplastic syndrome.
    Hirsch CM; Przychodzen BP; Radivoyevitch T; Patel B; Thota S; Clemente MJ; Nagata Y; LaFramboise T; Carraway HE; Nazha A; Sekeres MA; Makishima H; Maciejewski JP
    Haematologica; 2017 Jun; 102(6):1028-1034. PubMed ID: 28255022
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.
    Jain T; Ware AD; Dalton WB; Pasca S; Tsai HL; Gocke CD; Gondek LP; Xian RR; Borowitz MJ; Levis MJ
    Leuk Res; 2023 Aug; 131():107345. PubMed ID: 37354804
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeted next-generation sequencing using a multigene panel in myeloid neoplasms: Implementation in clinical diagnostics.
    Maes B; Willemse J; Broekmans A; Smets R; Cruys B; Put N; Madoe V; Janssen M; Soepenberg O; Bries G; Vrelust I; Achten R; Van Pelt K; Buvé K; Theunissen K; Peeters V; Froyen G
    Int J Lab Hematol; 2017 Dec; 39(6):604-612. PubMed ID: 28722833
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.
    Hamilton BK; Visconte V; Jia X; Tabarroki A; Makishima H; Hasrouni E; Abounader D; Kalaycio M; Sekeres MA; Sobecks R; Duong Liu H; Bolwell B; Maciejewski JP; Copelan E; Tiu RV
    Am J Hematol; 2016 Jun; 91(4):406-9. PubMed ID: 26799334
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ASXL1 is a molecular predictor in idiopathic cytopenia of undetermined significance.
    Shin DY; Park JK; Kim SM; Im K; Kim JA; Kim SY; Hwang SM; Yoon SS; Lee DS
    Leuk Lymphoma; 2019 Mar; 60(3):756-763. PubMed ID: 30301403
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis.
    Li F; Qin T; Li B; Qu S; Pan L; Zhang P; Sun Q; Cai W; Gao Q; Jiao M; Li J; Ai X; Ma J; Gale RP; Xu Z; Xiao Z
    Leukemia; 2024 Jun; 38(6):1334-1341. PubMed ID: 38714876
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activating CBL mutations are associated with a distinct MDS/MPN phenotype.
    Schwaab J; Ernst T; Erben P; Rinke J; Schnittger S; Ströbel P; Metzgeroth G; Mossner M; Haferlach T; Cross NC; Hochhaus A; Hofmann WK; Reiter A
    Ann Hematol; 2012 Nov; 91(11):1713-20. PubMed ID: 23010802
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Myeloid Clonal Infiltrate Identified With Next-Generation Sequencing in Skin Lesions Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case Series.
    Martin de Frémont G; Hirsch P; Gimenez de Mestral S; Moguelet P; Ditchi Y; Emile JF; Senet P; Georgin-Lavialle S; Hanslik T; Maurier F; Adedjouma A; Abisror N; Mahevas T; Malard F; Adès L; Fenaux P; Fain O; Chasset F; Mekinian A
    Front Immunol; 2021; 12():715053. PubMed ID: 34671345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.